En español
NIDA

Cocaine

  1. Calatayud J, González A. History of the development and evolution of local anesthesia since the coca leaf. Anesthesiology. 2003;98(6):1503-1508.
  2. Goldstein RA, DesLauriers C, Burda AM. Cocaine: history, social implications, and toxicity–a review. Dis–Mon DM. 2009;55(1):6-38. doi:10.1016/j.disamonth.2008.10.002.
  3. Drent M, Wijnen P, Bast A. Interstitial lung damage due to cocaine abuse: pathogenesis, pharmacogenomics and therapy. Curr Med Chem. 2012;19(33):5607-5611.
  4. Center for Behavioral Health Statistics and Quality (CBHSQ). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. HHS Publication No. SMA 15-4927, NSDUH Series H-50.
  5. Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the Future National Survey Results on Drug Use: 1975-2015: Overview: Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2015.
  6. Center for Behavioral Health Statistics and Quality (CBHSQ). Drug Abuse Warning Network: 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
  7. Riezzo I, Fiore C, De Carlo D, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem. 2012;19(33):5624-5646.
  8. Baik J-H. Dopamine signaling in reward-related behaviors. Front Neural Circuits. 2013;7. doi:10.3389/fncir.2013.00152.
  9. Schmidt HD, Pierce RC. Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann N Y Acad Sci. 2010;1187:35-75. doi:10.1111/j.1749-6632.2009.05144.x.
  10. Wolf ME. The Bermuda Triangle of cocaine-induced neuroadaptations. Trends Neurosci. 2010;33(9):391-398. doi:10.1016/j.tins.2010.06.003.
  11. Mantsch JR, Vranjkovic O, Twining RC, Gasser PJ, McReynolds JR, Blacktop JM. Neurobiological mechanisms that contribute to stress-related cocaine use. Neuropharmacology. 2014;76, Part B:383-394. doi:10.1016/j.neuropharm.2013.07.021.
  12. Lucantonio F, Stalnaker TA, Shaham Y, Niv Y, Schoenbaum G. The impact of orbitofrontal dysfunction on cocaine addiction. Nat Neurosci. 2012;15(3):358-366. doi:10.1038/nn.3014.
  13. Lucantonio F, Takahashi YK, Hoffman AF, et al. Orbitofrontal activation restores insight lost after cocaine use. Nat Neurosci. 2014;17(8):1092-1099. doi:10.1038/nn.3763.
  14. Spronk DB, van Wel JHP, Ramaekers JG, Verkes RJ. Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev. 2013;37(8):1838-1859. doi:10.1016/j.neubiorev.2013.07.003.
  15. Advokat C, Comaty J, Julien R. Julien’s Primer of Drug Action. 13th ed. New York, NY: Worth Publishers; 2014.
  16. Fonseca AC, Ferro JM. Drug abuse and stroke. Curr Neurol Neurosci Rep. 2013;13(2):325. doi:10.1007/s11910-012-0325-0.
  17. Pennings EJM, Leccese AP, Wolff FA de. Effects of concurrent use of alcohol and cocaine. Addict Abingdon Engl. 2002;97(7):773-783.
  18. Büttner A. Neuropathological alterations in cocaine abuse. Curr Med Chem. 2012;19(33):5597-5600.
  19. Mateos-García A, Roger-Sánchez C, Rodriguez-Arias M, et al. Higher sensitivity to the conditioned rewarding effects of cocaine and MDMA in High-Novelty-Seekers mice exposed to a cocaine binge during adolescence. Psychopharmacology (Berl). 2015;232(1):101-113. doi:10.1007/s00213-014-3642-y.
  20. Maraj S, Figueredo VM, Lynn Morris D. Cocaine and the heart. Clin Cardiol. 2010;33(5):264-269. doi:10.1002/clc.20746.
  21. Sinha R. The clinical neurobiology of drug craving. Curr Opin Neurobiol. 2013;23(4):649-654. doi:10.1016/j.conb.2013.05.001.
  22. Khalsa JH, Elkashef A. Interventions for HIV and hepatitis C virus infections in recreational drug users. Clin Infect Dis. 2010;50(11):1505-1511. doi:10.1086/652447.
  23. Buch S, Yao H, Guo M, et al. Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res. 2012;10(5):425-428.
  24. Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B. Substance abuse, HIV-1 and hepatitis. Curr HIV Res. 2012;10(7):557-571.
  25. Wendell AD. Overview and epidemiology of substance abuse in pregnancy. Clin Obstet Gynecol. 2013;56(1):91-96. doi:10.1097/GRF.0b013e31827feeb9.
  26. Cain MA, Bornick P, Whiteman V. The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy. Clin Obstet Gynecol. 2013;56(1):124-132. doi:10.1097/GRF.0b013e31827ae167.
  27. Hull L, May J, Farrell-Moore D, Svikis DS. Treatment of cocaine abuse during pregnancy: translating research to clinical practice. Curr Psychiatry Rep. 2010;12(5):454-461. doi:10.1007/s11920-010-0138-2.
  28. Schottenfeld RS, Moore B, Pantalon MV. Contingency management with community reinforcement approach or twelve-step facilitation drug counseling for cocaine dependent pregnant women or women with young children. Drug Alcohol Depend. 2011;118(1):48-55. doi:10.1016/j.drugalcdep.2011.02.019.
  29. Behnke M, Smith VC, Abuse C on S, Newborn C on FA. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131(3):e1009-e1024. doi:10.1542/peds.2012-3931.
  30. Gouin K, Murphy K, Shah PS, Knowledge Synthesis group on Determinants of Low Birth Weight and Preterm Births. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204(4):340.e1-e12. doi:10.1016/j.ajog.2010.11.013.
  31. Lambert BL, Bauer CR. Developmental and behavioral consequences of prenatal cocaine exposure: a review. J Perinatol Off J Calif Perinat Assoc. 2012;32(11):819-828. doi:10.1038/jp.2012.90.
  32. Lester BM, Lagasse LL. Children of addicted women. J Addict Dis. 2010;29(2):259-276. doi:10.1080/10550881003684921.
  33. Ackerman JP, Riggins T, Black MM. A review of the effects of prenatal cocaine exposure among school-aged children. Pediatrics. 2010;125(3):554-565. doi:10.1542/peds.2009-0637.
  34. Buckingham-Howes S, Berger SS, Scaletti LA, Black MM. Systematic review of prenatal cocaine exposure and adolescent development. Pediatrics. 2013;131(6):e1917-e1936. doi:10.1542/peds.2012-0945.
  35. Li K, Zhu D, Guo L, et al. Connectomics signatures of prenatal cocaine exposure affected adolescent brains. Hum Brain Mapp. 2013;34(10):2494-2510. doi:10.1002/hbm.22082.
  36. Center for Behavioral Health Statistics and Quality (CBHSQ). Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934.
  37. Shorter D, Domingo CB, Kosten TR. Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drugs. 2015;20(1):15-29. doi:10.1517/14728214.2015.985203.
  38. Karila L, Reynaud M, Aubin H-J, et al. Pharmacological treatments for cocaine dependence: is there something new? Curr Pharm Des. 2011;17(14):1359-1368.
  39. Kampman KM. What’s new in the treatment of cocaine addiction? Curr Psychiatry Rep. 2010;12(5):441-447. doi:10.1007/s11920-010-0143-5.
  40. Harvey-Lewis C, Li Z, Higgins GA, Fletcher PJ. The 5-HT2C receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology. 2016;101:237-245. doi:10.1016/j.neuropharm.2015.09.028.
  41. Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(11):1401-1407. doi:10.1016/j.euroneuro.2013.05.014.
  42. Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013;23(7):333-340. doi:10.1097/FPC.0b013e328361c39d.
  43. Kosten TR, Wu G, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry. 2013;73(3):219-224. doi:10.1016/j.biopsych.2012.07.011.
  44. Kosten TR, Domingo CB. Can you vaccinate against substance abuse? Expert Opin Biol Ther. 2013;13(8):1093-1097. doi:10.1517/14712598.2013.791278.
  45. Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009;66(10):1116-1123. doi:10.1001/archgenpsychiatry.2009.128.
  46. Cai X, Tsuchikama K, Janda KD. Modulating cocaine vaccine potency through hapten fluorination. J Am Chem Soc. 2013;135(8):2971-2974. doi:10.1021/ja400356g.
  47. Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines. 2013;12(3):323-332. doi:10.1586/erv.13.1.
  48. Nielsen DA, Hamon SC, Kosten TR. The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet. 2013;23(6):225-232. doi:10.1097/YPG.0000000000000008.
  49. Schindler CW, Goldberg SR. Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity. Future Med Chem. 2012;4(2):163-175. doi:10.4155/fmc.11.181.
  50. Penberthy JK, Ait-Daoud N, Vaughan M, Fanning T. Review of treatment for cocaine dependence. Curr Drug Abuse Rev. 2010;3(1):49-62.
  51. Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM. A randomized trial adapting contingency management targets based on initial abstinence status of cocaine-dependent patients. J Consult Clin Psychol. 2012;80(2):276-285. doi:10.1037/a0026883.
  52. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320-331.
  53. Petry NM, Alessi SM, Rash CJ. Contingency management treatments decrease psychiatric symptoms. J Consult Clin Psychol. 2013;81(5):926-931. doi:10.1037/a0032499.
  54. Carroll KM, Ball SA, Martino S, et al. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry. 2008;165(7):881-888. doi:10.1176/appi.ajp.2008.07111835.
  55. Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA, Rounsaville BJ. Enduring effects of a computer-assisted training program for cognitive behavioral therapy: a 6-month follow-up of CBT4CBT. Drug Alcohol Depend. 2009;100(1-2):178-181. doi:10.1016/j.drugalcdep.2008.09.015.
  56. Carroll KM, Kiluk BD, Nich C, et al. Computer-assisted delivery of cognitive-behavioral therapy: efficacy and durability of CBT4CBT among cocaine-dependent individuals maintained on methadone. Am J Psychiatry. 2014;171(4):436-444. doi:10.1176/appi.ajp.2013.13070987.
  57. Vanderplasschen W, Colpaert K, Autrique M, et al. Therapeutic communities for addictions: a review of their effectiveness from a recovery-oriented perspective. Sci World J. 2013;2013, 2013:e427817. doi:10.1155/2013/427817.
  58. Leon GD. Is the therapeutic community an evidence based treatment? What the evidence says. Ther Communities Int Jdournal Ther Support Organ. 2010;31(2):104-128.
  59. McKay JR, Van Horn D, Rennert L, Drapkin M, Ivey M, Koppenhaver J. Factors in sustained recovery from cocaine dependence. J Subst Abuse Treat. 2013;45(2):163-172. doi:10.1016/j.jsat.2013.02.007.
  60. Farabee D, Cousins SJ, Brecht M-L, et al. A comparison of four telephone-based counseling styles for recovering stimulant users. Psychol Addict Behav. 2013;27(1):223-229. doi:10.1037/a0029572.
  61. Van Horn DHA, Drapkin M, Ivey M, et al. Voucher incentives increase treatment participation in telephone-based continuing care for cocaine dependence. Drug Alcohol Depend. 2011;114(2-3):225-228. doi:10.1016/j.drugalcdep.2010.09.007.
  62. Donovan DM, Daley DC, Brigham GS, et al. Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network. J Subst Abuse Treat. 2013;44(1):103-114. doi:10.1016/j.jsat.2012.04.004.
  63. Agrawal A, Verweij KJH, Gillespie NA, et al. The genetics of addiction-a translational perspective. Transl Psychiatry. 2012;2:e140. doi:10.1038/tp.2012.54.
  64. Drgon T, Zhang P-W, Johnson C, et al. Genome wide association for addiction: replicated results and comparisons of two analytic approaches. PloS One. 2010;5(1):e8832. doi:10.1371/journal.pone.0008832.
  65. Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest. 2012;122(10):3387-3393. doi:10.1172/JCI60390.
  66. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76 Pt B:259-268. doi:10.1016/j.neuropharm.2013.04.004.
  67. Schmidt HD, McGinty JF, West AE, Sadri-Vakili G. Epigenetics and psychostimulant addiction. Cold Spring Harb Perspect Med. 2013;3(3):a012047. doi:10.1101/cshperspect.a012047.
  68. Vassoler FM, Sadri-Vakili G. Mechanisms of transgenerational inheritance of addictive-like behaviors. Neuroscience. 2014;264:198-206. doi:10.1016/j.neuroscience.2013.07.064.
  69. Young KA, Franklin TR, Roberts DCS, et al. Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues. J Neurosci Off J Soc Neurosci. 2014;34(14):5038-5043. doi:10.1523/JNEUROSCI.4977-13.2014.
  70. Gu H, Salmeron BJ, Ross TJ, et al. Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity. NeuroImage. 2010;53(2):593-601. doi:10.1016/j.neuroimage.2010.06.066.
  71. McHugh MJ, Demers CH, Salmeron BJ, Devous MD, Stein EA, Adinoff B. Cortico-amygdala coupling as a marker of early relapse risk in cocaine-addicted individuals. Front Psychiatry. 2014;5:16. doi:10.3389/fpsyt.2014.00016.
  72. Wisner KM, Patzelt EH, Lim KO, MacDonald AW. An intrinsic connectivity network approach to insula-derived dysfunctions among cocaine users. Am J Drug Alcohol Abuse. 2013;39(6):403-413. doi:10.3109/00952990.2013.848211.
  73. Kelly C, Zuo X-N, Gotimer K, et al. Reduced interhemispheric resting state functional connectivity in cocaine addiction. Biol Psychiatry. 2011;69(7):684-692. doi:10.1016/j.biopsych.2010.11.022.
  74. Connolly CG, Bell RP, Foxe JJ, Garavan H. Dissociated grey matter changes with prolonged addiction and extended abstinence in cocaine users. PLoS ONE. 2013;8(3):e59645. doi:10.1371/journal.pone.0059645.
  75. Bell RP, Foxe JJ, Ross LA, Garavan H. Intact inhibitory control processes in abstinent drug abusers (I): a functional neuroimaging study in former cocaine addicts. Neuropharmacology. 2014;82:143-150. doi:10.1016/j.neuropharm.2013.02.018.

This page was last updated May 2016

Get this Publication

Cite this article

APA style citation

NIDA (2016). Cocaine. Retrieved , from https://www.drugabuse.gov/publications/research-reports/cocaine

press ctrl+c to copy
NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.